Table 4.

Latest international recommendations for the switch to oral two-drug regimens in patients who achieved virological control with three-drug cART.

Regimen	DHHS 2021 [2]	IAS-USA 2020 [3]	EACS 2020 [4]
DTG+RPV	Recommended [AI] a	Recommended [AIa] c	Recommended e
DTG+3TC	Recommended [AI] a	Recommended [AIa] c	Recommended e
DRV/r+3TC	Alternative [BI] b	Alternative [AIa] d	Recommended e
ATV/r+3TC	Alternative [CI] b	Alternative [AIa] d	Recommended e
LPV/r+3TC	Alternative [CI] b	Alternative [AIa] d	-
DRV/r+RPV	-	-	Recommended [supported only by small trials] f
DRV/r+DTG	Alternative [CI]	-	Recommended [supported only by small trials] f

^a In the absence of documented drug-resistance and HBV co-infection. ^b When the use of tenofovir disoproxil, tenofovir alafenamide, or abacavir is contraindicated or not desirable. ^c In patients with no prior virological failure or drug resistance, and no HBV co-infection. ^d When other NRTIs or dolutegravir cannot be used. ^e In patients with no prior virological failure or drug resistance. ^f Only to persons with (a) no historical resistance, (b) suppression of HIV viral load to <50 copies/mL for at least the past 6 months and (c) absence of chronic HBV co-infection. ATV/r = atazanavir/ritonavir; cART = combination antiretroviral therapy; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EACS = European AIDS Clinical Society; DHHS = U.S. Department of Health and Human Services; IAS = International AIDS Society; LPV/r = lopinavir/ritonavir; RPV = rilpivirine; VL = viral load. The strength of recommendations is reported as in each guideline.